{
    "nctId": "NCT03934905",
    "briefTitle": "Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction",
    "officialTitle": "Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)",
    "overallStatus": "RECRUITING",
    "conditions": "Anthracycline Related Cardiotoxicity in Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 to 89 years\n2. No prior diagnosis of coronary artery, carotid artery or peripheral artery disease\n3. Not pregnant or breastfeeding (urine pregnancy test will be done if female of childbearing potential)\n4. Breast cancer requiring treatment with DOX-containing regimen above\n5. Women in child bearing age group (18-50 years) will agree to use birth control for duration of study\n6. Study subjects must be willing and able to swallow caplets, up to 8 daily.\n\nExclusion Criteria:\n\n1. Currently on a research study with an investigational drug, or has been on one in the previous 30 days\n2. Pregnant (by urine pregnancy test)\n3. Baseline ejection fraction of less than 50%, evidence of left ventricular hypertrophy or baseline EKG reported as abnormal per cardiologist.\n4. Inability to provide informed consent.\n5. Prior history of chest radiation therapy\n6. Diabetes or Hypertension or prior Myocardial infarction\n7. Trastuzumab patients\n8. Routinely taking vegetable or fruit-containing supplement pills (antioxidant phytochemicals) (daily vitamin pills ok)\n9. Inability to follow up for safety monitoring\n10. Prisoners\n11. Previous or current use of cocaine or any illicit drug\n12. Unable or unwilling to provide blood samples\n13. Taking medications known to have cardiac effects, such as but not limited to, beta blockers, anti-arrhythmic agents, non dihydropyridine calcium channel blockers, ace inhibitors, NSAIDS, diuretic agents.\n14. Unable to follow the protocol\n15. Inability to receive anthracycline due to any reason (underlying baseline cardiac dysfunction due to other reasons, with an EF under 50%)\n16. Patients already taking SFN OTC",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}